Inclusion Criteria:

- Performance status of 0 to 1 on the Eastern Cooperative Oncology Group (ECOG) Scale.

- Previously untreated, histological documented, inoperable stage IIIA or IIIB squamous
cell carcinoma of lung, excluding those with pericardial, pleural effusion, and those
with contralateral hilar or contralateral supraclavicular lymph nodes.

- Patients must have measurable disease according to RECIST criteria, and all
detectable tumor can be encompassed by radiation therapy fields.

- Weight loss ≦ 5% in the previous six months.

- Patient must have adequate blood, liver, lungs and kidney function within the
requirements of this study.

- Female patients of child-bearing potential must test negative for pregnancy at the
time of enrollment based on a serum pregnancy test. Male and female patients must
agree to use a reliable method of birth control during and for 3 months following the
last dose of study drug.

- Patients must sign a study-specific informed consent form prior to study entry.

Exclusion Criteria:

- Complete tumor resection, recurrent disease, or those patients eligible for
definitive surgery.

- Previous chemotherapy or previous biologic response modifiers for current lung
cancer.

- Patient has previously had thoracic radiation therapy.

- Prior or concurrent malignancy except non-melanomatous skin cancer unless
disease-free for five years or more.

- Serious concomitant disorders that would compromise the safety of the patient, or
compromise the patient's ability to complete the study, at the discretion of the
investigator.

- History of significant neurological or mental disorder, including seizures or
dementia.